Figure 2
From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Incidence of any grade and grade ≥ 3 adverse events (AEs) by cycle for patients with relapsed/refractory peripheral or cutaneous T-cell lymphoma (PTCL, CTCL). Numbered bars represent number of patients treated in each cycle.